Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Anti-aging pill? singapore trial tests AKG on biological age

NCT ID NCT05706389

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking alpha-ketoglutarate (AKG), a natural substance in the body, can lower biological age in 120 middle-aged adults from Singapore. Participants must have a biological age older than their actual age. The study measures changes in DNA methylation (a marker of aging) and other health indicators over 6 months. It aims to see if aging can be slowed down with a simple supplement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * participants whose biological age (as measured by blood DNA methylation) is greater than their chronological age Exclusion Criteria: * pregnant women * more than ONE of the following chronic medical conditions (based on the medical history and during screening), they are NOT eligible to participate in the study: 1. Waist circumference more than or equal to 90 cm for males or more than or equal to 80 cm for females 2. Fasting triglycerides more than or equal to 1.7 mmol/l 3. High-density lipoprotein less than 1.0 mmol/l in men or less than 1.3 mmol/l in women 4. Blood pressure more than or equal to 130/85 mmHg or use of antihypertensive medication 5. Fasting glucose more than or equal to 6.0 mmol/l 6. Osteopenia 7. Mild Osteoarthritis not interfering in daily activities 8. Fatty liver * Participants will NOT be recruited if they fall in the following categories: 1. Pre-existing, or history of major CVD (coronary artery disease, heart failure, stroke, peripheral vascular disease, pulmonary hypertension), severe/uncontrolled hypertension (under 3 or more than 3 prescribed medications), rheumatic heart disease, congenital heart disease, deep vein thrombosis, pulmonary embolism 2. Type 1 diabetes and Type 2 diabetes under oral metformin or insulin therapy and with diabetic complications such as diabetic retinopathy, diabetic nephropathy 3. Active cancer or treatment of cancer in the last 3 years 4. Chronic obstructive pulmonary disease (COPD), severe asthma (taking daily medications) 5. Pregnant women will not be recruited into this study because of the safety issues associated with X-ray irradiation during DXA scan 6. Potential female participants who plan on pregnancy within the next 9 months of study period 7. Multiple sclerosis and autoimmune/immune deficiency diseases such as Rheumatic arthritis, HIV, Crohn's disease 8. Recent history of sepsis or infection (within 3 months of in-patient hospitalization) 9. Any psychiatric disease or neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, Lewy body dementia, and any eating disorders 10. Any metal implants in the body 11. Hepatitis and Liver cirrhosis (independent of severity) 12. Severe kidney disease (GFR less than 30 ml/min/1.73 m2) 13. Skin disease (on oral or systemic medication for immune system) 14. Subjects receiving any other similar investigational product within 60 days or 5 halflives before the screening, whichever that is longer 15. Any serious medical illness which in the PI's judgment may jeopardize the subject by his or her participation in this study or may hamper his or her ability to perform and complete procedures required in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre for Healthy Longevity, Alexandra Hospital

    Singapore, 159964, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.